Is Ozempic a tirzepatide? The difference explained clearly

What the clinical evidence tells us about semaglutide and tirzepatide

The clearest way to answer whether ozempic and tirzepatide are related is to start where the evidence starts: in the clinical trials. Semaglutide 2.4mg (Wegovy) was tested in the STEP 1 trial over 68 weeks, with participants losing an average of around 15% of body weight, as published in the New England Journal of Medicine. Tirzepatide was tested in the SURMOUNT-1 trial, involving 2,539 adults with obesity, over 72 weeks, where the highest dose produced average reductions of around 20–21% of body weight. Then came SURMOUNT-5, a direct head-to-head trial published in 2025, in which tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. NICE reviewed both bodies of evidence separately: tirzepatide is recommended under NICE technology appraisal TA1026, and semaglutide (Wegovy) under TA875. These are distinct medicines with separate regulatory histories.

One misconception worth clearing up gently: some people assume Ozempic and Mounjaro are simply different-brand versions of the same drug, and if you have found yourself wondering are Ozempic and tirzepatide the same, the short answer is no. Their active ingredients, their molecular targets, and their licensed indications differ in important ways. The confusion is understandable given how often both appear together in conversations about weight loss, but the distinction matters clinically.

How semaglutide and tirzepatide differ as medicines

Semaglutide activates GLP-1 receptors, slowing gastric emptying and reducing appetite. Tirzepatide targets both GLP-1 and GIP receptors simultaneously, making it the only dual-agonist weight-loss medicine currently licensed in the UK. People often ask is tirzepatide like Ozempic, and while the two share some broad similarities in how they reduce appetite, the underlying mechanisms are meaningfully different. Whether that translates into a meaningful difference for any individual patient is exactly the kind of question a prescriber works through with you. You can read more about how the two stack up in practice on our Wegovy vs Mounjaro comparison page.

What is licensed for weight loss in the UK, and what is not

The NHS medicines page for semaglutide confirms that Ozempic is licensed for type 2 diabetes, not weight management. Using it for weight loss would be off-label. The MHRA, which licenses medicines in the UK, has been explicit that GLP-1 medicines are not assessed or approved for cosmetic or quick weight loss. A common source of confusion is the question of whether Ozempic is tirzepatide or semaglutide, and the answer is that Ozempic contains semaglutide, a separate active ingredient from tirzepatide. Both require a prescription following clinical assessment. Wegovy is also available as an oral tablet, approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK.

At nume, our GPhC-registered pharmacy dispenses Mounjaro and Wegovy for eligible adults. Neither Ozempic nor any off-label semaglutide prescription forms part of what we offer for weight management. If you are considering whether tirzepatide or semaglutide (Wegovy) is the better fit for you, our page covering whether tirzepatide is the same as Ozempic goes into more detail on the practical differences, and a fuller side-by-side comparison is covered on our Wegovy and Mounjaro side-by-side page. Our clinical team, led by our clinical lead, reviews every consultation personally before any prescription is issued.

How to explore your options safely

Both Mounjaro and Wegovy are prescription-only medicines. The only legal route to either of them in the UK is a prescription issued after a clinical assessment. That assessment considers your BMI, any existing conditions, your current medicines, and your goals. For tirzepatide under NICE guidance, adults need a BMI of 35 or above alongside at least one weight-related condition; for some ethnic backgrounds, the threshold is 2.5 kg/m² lower. Private eligibility follows the licensed criteria, which set the threshold at BMI 30 or above, or 27 with a relevant health condition. The prescriber, not a checklist, makes that call. A broader overview of weight-loss treatment options is on our weight-loss treatments overview.

If you have questions that are not covered here, our FAQs cover a wide range of common queries. You can also reach the team directly via our contact page. Which medicine suits you is a clinical decision our prescribers make with you, not something to settle on from a search result. Check your eligibility and start a free consultation at our treatment page.